Tim Smith

This new post-hoc analysis of ruxolitinib cream for those with eczema indicates that continued treatment past 8 weeks may lead to further benefit for those with the skin disease.

This segment of Dr. Okoye’s interview featured a set of examples of HS patients’ struggles with access to medication, as well as discussion of potential solutions.

This new data was presented at EADV in Berlin, with the findings of 3 studies expanding the range of effectiveness of this treatment to 140-weeks for patients with eczema.

This interview with Dr. Okoye featured a discussion about her presentation at the SHSA conference, specifically regarding healthcare disparities for HS patients.

In this interview, Dr. Simpson discussed the latest findings presented at EADV in Berlin on the use of tapinarof cream, 1% for adults and children as young as 2 years with eczema.

The findings from these 2 trials for bimekizumab may lead to greater treatment options for patients with HS, an often debilitating and chronic skin condition.

The new data on this drug’s effects on maintenance of clinical response indicates the strength of the treatment for individuals with the immune-mediated skin disease.

The new results from 3 different phase 3 studies presented at EADV on nemolizumab for those with prurigo nodularis and eczema show promise for the treatment.

This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.

This new data on the negative impacts of skin disease on individuals in 27 countries in Europe demonstrates the lasting impacts of stigmatization.

This new recommendation by the European Academy of Allergy and Clinical Immunology was put forward to help guide clinical practices.

This new data represents the first real-world, US-based data on this drug, demonstrating the efficacy and the safety indications of these clinical trials.

This new data from 27 European countries resulted in several notable findings with regard to the journey of patients with skin disease in various healthcare environments.

This decision by the FDA could offer psoriatic arthritis patients a dosing regimen each month that does not require pre-mediation or regular lab assessments.

This new research could allow for limitations related to safety that could promote mitigation of ambient air pollution and protect those with allergies.

This announcement by Arcutis broadens the psoriasis drug’s indication and was done to help simplify management of the skin condition for younger patients as well.

This new data may help clinicians not to over-treat or over-medicalize with infants that have a SARS-CoV-2 infection.

This new analysis was described as the first estimate on the prevalence in Europe of specific TNA and sensitization.

This new synthetic data set could work as a potential resource for training on AI as well as to help facilitate a consensus among clinicians.

Amid the escalating threat of wildfires due to climate change, the medical and public health communities face an increasing responsibility to develop robust emergency response plans to safeguard patients and healthcare infrastructure.

The investigators of this new data note that integration using a standardized process which is EMR-based may be the next thing to move for, to better address the overreporting of penicillin allergy.

This interview segment with Dr. Harris-Tryon further explored some of the key points made in her upcoming talk regarding the microbiology of hidradenitis suppurativa.

During this interview, Dr. Harris-Tryon spoke about the most important points covered in her upcoming talk at the 8th Annual Symposium on Hidradenitis Suppurativa Advances.

This new data indicated that BHRA positivity could potentially be implemented as an omalizumab response predictor and showed the potential for off-label use.

This news was announced following new findings by the FDA due to a recent inspection, though no concerns were listed regarding clinical data, labeling, or safety.

This study indicated the potential of PDLs as a strategy for those that have HDHP-HSAs to address both patient access and affordability of asthma care.

This new data resulted from the first study that found EIS could detect skin barrier dysfunction among children found to have developed atopic dermatitis early on in life.

This new research into detergent’s impact on human skin barrier dysfunction may lead to investigation by public health authorities in the near future due to its implications.

This new position statement by the Congress of the European Academy of Dermatology and Venereology identified several benefits to the implementation of technological innovations in dermatologic care.

This set of measures may promote a more accurate assessment of HS in patients as well as on their life outcomes, with the goal being shared decision-making in clinical practice.